Overview
flowchart TD
companies_pd_mitochondrial_neu["Parkinsons Disease Mitochondrial Neuroprotectio"]
style companies_pd_mitochondrial_neu fill:#4fc3f7,stroke:#333,color:#000
companies_pd_mitocho_0["Key Companies"]
companies_pd_mitochondrial_neu -->|"includes"| companies_pd_mitocho_0
style companies_pd_mitocho_0 fill:#81c784,stroke:#333,color:#000
companies_pd_mitocho_1["Vandria SA"]
companies_pd_mitochondrial_neu -->|"includes"| companies_pd_mitocho_1
style companies_pd_mitocho_1 fill:#ef5350,stroke:#333,color:#000
companies_pd_mitocho_2["NeuroMito Therapeutics"]
companies_pd_mitochondrial_neu -->|"includes"| companies_pd_mitocho_2
style companies_pd_mitocho_2 fill:#ffd54f,stroke:#333,color:#000
companies_pd_mitocho_3["Clene Nanomedicine"]
companies_pd_mitochondrial_neu -->|"includes"| companies_pd_mitocho_3
style companies_pd_mitocho_3 fill:#ce93d8,stroke:#333,color:#000
companies_pd_mitocho_4["Napa Therapeutics"]
companies_pd_mitochondrial_neu -->|"includes"| companies_pd_mitocho_4
style companies_pd_mitocho_4 fill:#4fc3f7,stroke:#333,color:#000
companies_pd_mitocho_5["Mitothera"]
companies_pd_mitochondrial_neu -->|"includes"| companies_pd_mitocho_5
style companies_pd_mitocho_5 fill:#81c784,stroke:#333,color:#000
...
Overview
Mermaid diagram (expand to render)
This category covers biotechnology and pharmaceutical companies developing mitochondrial-targeted neuroprotection therapies for Parkinson's disease. These approaches address the fundamental mitochondrial dysfunction that is a central pathological feature in PD, including Complex I deficiency, impaired mitophagy, oxidative stress, and defective mitochondrial dynamics.
The rationale for mitochondrial-targeted therapies in PD is strong, supported by both genetic evidence (PINK1, PARKIN, DJ-1 mutations causing familial PD) and environmental evidence (MPTP, rotenone, pesticides causing mitochondrial Complex I inhibition and PD-like syndromes)[@schapira2014].
Key Companies
Vandria SA
Focus : Mitochondrial quality control and mitophagy inductionLead Candidate : VNA-100Indication : Parkinson's diseaseStage : Preclinical/IND-enablingMechanism : Mitophagy inducer targeting the PINK1-PARKIN pathwayNotes : Swiss-based company with dual programs in AD (VNA-318) and PD (VNA-100)Page : [Vandria SA](/companies/vandria)NeuroMito Therapeutics
Focus : Mitochondrial antioxidantsLead Candidate : NMT-101Indication : Parkinson's diseaseStage : Phase 2Mechanism : Mitochondria-targeted nitroxide compound (TPP moiety) for selective ROS scavengingNotes : Based in Boston, Series C funded in 2025Page : [NeuroMito Therapeutics](/companies/Neuromito-therapeutics)Clene Nanomedicine
Focus : Catalytic nanotherapeutic approachLead Candidate : CNM-Au8Indication : Parkinson's disease (and ALS)Stage : Phase 2Mechanism : Gold nanocrystals catalyze redox reactions to support mitochondrial function and reduce oxidative stressNotes : Oral bioavailability, crosses blood-brain barrierPage : [Clene Nanomedicine](/companies/clene-nanomedicine)Napa Therapeutics
Focus : Mitochondrial protectionLead Candidate : NP-101Indication : Parkinson's diseaseStage : Phase 1Mechanism : Mitochondria-targeted therapeuticPage : [Napa Therapeutics](/companies/napa-therapeutics)Mitothera
Focus : Mitochondrial protectantsLead Candidate : MT-101Indication : Neurodegeneration (including PD)Stage : PreclinicalMechanism : CoQ10-based mitochondrial protectant with ubiquinone moiety for direct ROS scavengingPage : [Mitothera](/companies/mitothera)Mechanism Categories
Mitochondrial Antioxidants Companies developing antioxidants specifically targeted to mitochondria using lipophilic cations (TPP - triphenylphosphonium) that accumulate in the mitochondrial matrix due to the mitochondrial membrane potential:
NeuroMito Therapeutics (NMT-101) : TPP-nitroxide conjugateMitoQ (not a company) : Mitoquinone - TPP-ubiquinoneSS-31 (elamipretide) : Mitochondria-targeted peptideMitophagy Inducers Companies targeting the PINK1-PARKIN pathway to enhance clearance of damaged mitochondria:
Vandria (VNA-100) : Small molecule mitophagy activatorCatalytic Antioxidants Companies using catalytic nanomaterials to support mitochondrial redox reactions:
Clene Nanomedicine (CNM-Au8) : Gold nanocrystalsCoQ10 Analogs and Precursors Companies developing CoQ10 analogues for Complex I support:
Mitothera (MT-101) : Ubiquinone-based mitochondrial protectantVarious nutraceutical companies
Clinical Pipeline Summary | Company | Drug | Mechanism | Phase | Status |
Scientific Rationale
Mitochondrial Dysfunction in PD Mitochondrial dysfunction is one of the most consistent pathological findings in Parkinson's disease:
Complex I deficiency : Observed in substantia nigra of sporadic PD patientsGenetic evidence : PINK1, PARKIN, DJ-1 mutations cause familial PD through mitophagy defectsEnvironmental evidence : MPTP, rotenone cause PD-like syndromes via Complex I inhibitionOxidative stress : Elevated ROS, reduced glutathione, increased lipid peroxidationTherapeutic Target Rationale Mitochondrial-targeted approaches offer several advantages:
Direct delivery : TPP-based compounds accumulate >100-fold in mitochondriaMechanism specificity : Target the precise cellular compartment affected in PDDisease modification potential : Address upstream pathology rather than symptomsBiomarker potential : Mitochondrial function can be monitored via CSF biomarkers
Cross-References
[Mitochondrial Dysfunction in Parkinson's Disease](/mechanisms/mitochondrial-dysfunction-parkinsons)
[Oxidative Stress in Neurodegeneration](/mechanisms/oxidative-stress-neurodegeneration)
[Parkinson's Disease](/diseases/parkinsons-disease)
[PINK1 Gene](/genes/pink1)
[PARKIN Gene](/genes/parkin)
[DJ-1 Gene](/genes/dj-1)
[Alpha-Synuclein](/proteins/alpha-synuclein)
[Neuroprotection](/mechanisms/neuroprotection-pathway)
See Also
[Parkinson's Disease](/diseases/parkinsons-disease)
[Mitochondrial Antioxidants](/therapeutics/mitochondrial-antioxidants-neurodegeneration)
[Oxidative Stress](/mechanisms/oxidative-stress)
[Neuroprotection](/treatments/neuroprotection)
[Clinical Trials](/clinical-trials)
References
[NeuroMito Therapeutics Corporate Website](https://www.neuromito.com)
[Vandria SA - Mitochondrial Therapeutics](https://www.vandria.com)
[Clene Nanomedicine - CNM-Au8](https://clene.com)
[Napa Therapeutics Corporate Website](https://www.napatherapeutics.com)
[Mitothera Corporate Website](https://www.mitothera.com)
[Greene JG, et al., Current concepts in mitochondrial neuroprotection in Parkinson's disease (2024)](https://pubmed.ncbi.nlm.nih.gov/38545678/)
[Schapira AH, et al., Mitochondrial pathology in Parkinson's disease (2014)](https://pubmed.ncbi.nlm.nih.gov/25424913/)
[Bender A, et al., L-DOPA accelerates mitochondrial pathogenesis (2016)](https://doi.org/10.1038/nrneurol.2016.123)
Show full description